Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
TELA Bio Appoints Jeffrey Blizard as President
-
Pulse Oil Corp. Announces Timing For Resumption of Trading
-
Arax Investment Partners Acquires Schechter Investment Advisors, Broadening Midwestern Presence
-
Pinnacle Treatment Centers Introduces New Opioid Treatment Options in California: Sublocade and Vivitrol
-
Dimensional Fund Advisors Ltd. : Form 8.3 - RENEWI PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - PRIMARY HEALTH PROPERTIES - Ordinary Shares
-
SharpLink Announces Closing of $425,000,000 Private Placement Led by Consensys Software Inc., Will Become the Largest Publicly-Traded ETH Holder Globally
-
Dimensional Fund Advisors Ltd. : Form 8.3 - AMERICAN AXLE & MFG HOLDINGS - Ordinary Shares
-
Robex Reports Operational and Financial Results for Q1 2025
-
Konsolidator grants 810,000 warrants
-
Fancamp Announces Appointment of CIO
-
Plexus Issues Fiscal 2024 Sustainability Report
-
Regency Centers Receives Green Lease Leaders Platinum Recognition for Sustainability
-
Alpha Modus Holdings, Inc. CEO Affiliates To Exchange Preferred Stock for Common Stock, Demonstrating Confidence in Near Future Outlook
-
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
-
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
-
JTS Opens Second Idaho Facility, Creating 140 New Jobs and Expanding U.S. Manufacturing Footprint
-
Transactions in Connection with Share Buy-back Program
-
Joint Press Release of Constellation Software Inc. and Topicus.com Inc. -- Topicus.com Inc. completes acquisition of Cipal Schaubroeck in Belgium
-
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
-
Exhibit navigating the fight for liberty to open at the Hampton History Museum
-
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
-
CAPREIT to Invest in Canadian Housing Supply with Construction of 170 Residential Suites Within Existing Portfolio
-
Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access
-
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
-
WSP acquires specialist healthcare and life sciences consulting firm Lexica
-
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Filecoin Foundation and Randamu Enable Time-Locked Smart Contracts for the Decentralized Storage Economy
-
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
-
Bitmine Immersion Technologies, Inc. Announces Uplist to NYSE American Stock Exchange
-
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
-
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
-
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
-
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
-
FDA Accepts TransCon® CNP NDA for Priority Review
-
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
-
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
-
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/k
-
Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors
-
Lightbridge Completes Final Experiment Design for Designated ATR Core Position
-
Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
-
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
-
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
-
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Condi
-
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
-
Solésence Expands Debt Facilities to Fuel Growth Initiatives
-
Oportun Issues Letter to Stockholders and Mails Definitive Proxy Materials
-
CareCloud to Present on AI Innovation at Maxim Group’s 2025 Virtual Tech Conference on June 3, 2025
